Lipid Particle Nucleic Acid Delivery for Tumor Cell Drug Sensitivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting drug sensitivity in breast cancer cells are inefficient and prone to false negatives and false positives, particularly when determining the sensitivity of breast cancer cell groups to specific drugs, which can lead to inappropriate treatment strategies.
Innovation Solution
A method involving lipid particles with a lipid membrane and a first nucleic acid, including a promoter sequence of a marker gene and a reporter gene, is used to contact breast cancer cells, allowing for the detection and quantification of drug-sensitive cells by expressing a reporter protein, thereby accurately determining the drug sensitivity of the cell group.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PCR method or microarray method is used to detect marker gene transcripts, then drug sensitivity prediction is achieved, but false negatives and false positives occur reducing reliability
Solution Approach 1:
The patent introduces a reporter gene system as an intermediary between the marker gene and direct detection. The reporter gene (e.g., GFP, RFP) serves as a mediator that translates marker gene expression into visible fluorescent signals, enabling more reliable detection of drug-sensitive cells while reducing false negatives and false positives associated with direct PCR or microarray methods
Solution Approach 2:
The patent replaces the mechanical/chemical detection systems of PCR and microarray methods with a biological reporter system. Instead of using complex amplification and hybridization protocols, the invention uses fluorescent protein expression as a direct readout of marker gene activity, simplifying the detection process while improving reliability
2Productivity
If conventional detection methods are used, then drug sensitivity is determined, but the process is inefficient and time-consuming
Solution Approach 1:
The patent performs preliminary action by transfecting the reporter construct into cells before drug treatment. This allows the reporter system to be established in advance, so that when drug sensitivity determination is needed, the cells are already prepared with the detection mechanism in place, eliminating the need for complex post-treatment analysis and significantly reducing detection time
Solution Approach 2:
The invention replaces time-consuming PCR amplification and microarray hybridization steps with a simple fluorescent microscopy or flow cytometry readout. The reporter gene system allows direct visual or automated detection of drug-sensitive cells, dramatically improving productivity while minimizing time loss
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method effectively and accurately determines the drug sensitivity of breast cancer cell groups by efficiently introducing the nucleic acid into cells and measuring the expression of reporter proteins, reducing false-negative and false-positive results and providing a reliable index for treatment decisions.
Implementation Method 1
a first nucleic acid, including a promoter sequence of a marker gene for determining the characteristic and a reporter gene linked to a downstream of the promoter sequence to be functionable
Data Source
AI summary
According to one embodiment, a method for determining a characteristic of a tumor cell group, the method includes bringing a lipid particle including a lipid membrane and a first nucleic acid included in the lipid membrane into contact with the tumor cell group (the first nucleic acid including a promoter sequence of a marker gene for determining the characteristic and a reporter gene linked to a downstream of the promoter sequence to be functionable), culturing the tumor cell group, detecting the presence or absence or an amount of a signal from a reporter protein that is expressed from the reporter gene, in each tumor cell included in the tumor cell group, and counting the number of tumor cells having the characteristic that is measured from a result of the detecting.